|
CA2668689C
(en)
|
2006-11-08 |
2015-12-29 |
Neurocrine Biosciences Inc. |
Substituted 3-isobutyl-9,10-dimethoxy-1,3,4,6,7,11b-hexahydro-2h-pyrido[2,1-a]isoquinolin-2-ol compounds and methods relating thereto
|
|
EP2610254B1
(en)
|
2008-09-18 |
2015-11-25 |
Auspex Pharmaceuticals, Inc. |
Deuterated benzoquinoline derivatives as inhibitors of vesicular monoamine transporter 2
|
|
CN104744456A
(zh)
|
2010-06-01 |
2015-07-01 |
奥斯拜客斯制药有限公司 |
Vmat2的苯并喹啉酮抑制剂
|
|
WO2012000308A1
(zh)
*
|
2010-06-29 |
2012-01-05 |
中国药科大学 |
丁苯那嗪的拆分方法
|
|
US8351329B2
(en)
*
|
2010-09-14 |
2013-01-08 |
Cisco Technology, Inc. |
Universal load-balancing tunnel encapsulation
|
|
CN102285984B
(zh)
*
|
2010-11-25 |
2012-10-10 |
江苏威凯尔医药科技有限公司 |
(2R,3R,11bR)-二氢丁苯那嗪及相关化合物的制备方法
|
|
WO2012081031A1
(en)
*
|
2010-12-15 |
2012-06-21 |
Enaltec Labs Pvt. Ltd. |
Process for preparing tetrabenazine
|
|
US9550780B2
(en)
|
2012-09-18 |
2017-01-24 |
Auspex Pharmaceuticals, Inc. |
Formulations pharmacokinetics of deuterated benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
CN104684555A
(zh)
|
2012-09-18 |
2015-06-03 |
奥斯拜客斯制药有限公司 |
囊泡单胺转运体2的氘化苯并喹啉抑制剂的制剂药代动力学
|
|
JP2016506957A
(ja)
|
2013-01-31 |
2016-03-07 |
オースペックス・ファーマシューティカルズ・インコーポレイテッドＡｕｓｐｅｘ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． |
Ｖｍａｔ２のベンゾキノロン阻害剤
|
|
EP3049087A4
(en)
*
|
2013-09-27 |
2017-05-24 |
Auspex Pharmaceuticals, Inc. |
Benzoquinolone inhibitors of vmat2
|
|
AU2014357518A1
(en)
|
2013-12-03 |
2016-06-09 |
Auspex Pharmaceuticals, Inc. |
Methods of manufacturing benzoquinoline compounds
|
|
EP3099299A4
(en)
*
|
2014-01-27 |
2017-10-04 |
Auspex Pharmaceuticals, Inc. |
Benzoquinoline inhibitors of vesicular monoamine transporter 2
|
|
KR20160117596A
(ko)
|
2014-02-07 |
2016-10-10 |
오스펙스 파마슈티칼스, 인코포레이티드 |
신규 제약 제제
|
|
RU2021128797A
(ru)
|
2014-02-07 |
2021-11-26 |
Ньюрокрайн Байосайенсиз, Инк. |
Фармацевтические композиции, содержащие антипсихотическое лекарственное средство и ингибитор vmat2, и их применение
|
|
MY183499A
(en)
|
2014-02-13 |
2021-02-22 |
Incyte Corp |
Cyclopropylamines as lsd1 inhibitors
|
|
JP6635945B2
(ja)
*
|
2014-05-06 |
2020-01-29 |
ニューロクライン バイオサイエンシーズ，インコーポレイテッド |
多動性運動障害を処置するためのｖｍａｔ２インヒビター
|
|
CA2974540C
(en)
*
|
2015-02-06 |
2023-09-26 |
Neurocrine Biosciences, Inc. |
[9,10-dimethoxy-3-(2-methylpropyl)-1h,2h,3h,4h,6h,7h,11bh-pyrido-[2,1-a]isoquinolin-2-yl]methanol and compounds, compositions and methods relating thereto
|
|
PL3265085T3
(pl)
|
2015-03-06 |
2022-11-07 |
Auspex Pharmaceuticals, Inc. |
Sposoby leczenia zaburzeń związanych z nieprawidłowymi ruchami mimowolnymi
|
|
MA51438A
(fr)
|
2015-04-03 |
2021-04-14 |
Incyte Corp |
Composés hétérocycliques utilisés en tant qu'inhibiteurs de lsd1
|
|
WO2016210180A2
(en)
*
|
2015-06-23 |
2016-12-29 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors for treating neurological diseases or disorders
|
|
SG10202001219UA
(en)
|
2015-08-12 |
2020-03-30 |
Incyte Corp |
Salts of an lsd1 inhibitor
|
|
BR112018007118A2
(pt)
|
2015-10-09 |
2018-12-11 |
Teva Pharmaceuticals Int Gmbh |
método para tratar um distúrbio de deficiência de dopamina, método para melhorar o tempo motor ativo sem discinesia num paciente com doença de parkinson, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir o tempo motor inativo num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir flutuações de nível de dopamina estriatal num indivíduo com um distúrbio de deficiência de dopamina, método para reduzir discinesia num indivíduo com um distúrbio de deficiência de dopamina após um tratamento de longo prazo, composição farmacêutica e embalagem
|
|
MX381258B
(es)
|
2015-10-30 |
2025-03-12 |
Neurocrine Biosciences Inc |
Sales de valbenazina y polimorfos de las mismas.
|
|
US10160757B2
(en)
|
2015-12-23 |
2018-12-25 |
Neuroscrine Biosciences, Inc. |
Synthetic methods for preparation of (S)-(2R,3R,11bR)-3-isobutyl-9,10-dimethoxy-2,3,4,6,7,11b-hexahydro-1H-pyrido[2,1-a]isoquinolin-2-yl 2-amino-3-methylbutanoate di(4-methylbenzenesulfonate)
|
|
WO2017182916A1
(en)
*
|
2016-04-22 |
2017-10-26 |
Lupin Limited |
Novel process for preparation of tetrabenazine and deutetrabenazine
|
|
WO2018001335A1
(zh)
|
2016-06-29 |
2018-01-04 |
苏州科睿思制药有限公司 |
Nbi-98854的晶型及其制备方法和用途
|
|
KR20190062460A
(ko)
|
2016-10-06 |
2019-06-05 |
아시아 케미컬 인더스트리스 리미티드 |
발베나진의 고체상 형태
|
|
EP4400171A3
(en)
|
2016-12-02 |
2024-09-11 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating schizophrenia or schizoaffective disorder
|
|
EP3568394A1
(en)
|
2017-01-10 |
2019-11-20 |
Sandoz AG |
Crystalline valbenazine free base
|
|
EA201991786A1
(ru)
*
|
2017-01-27 |
2020-01-16 |
Нейрокрин Байосайенсиз, Инк. |
Способы введения некоторых vmat2-ингибиторов
|
|
WO2018153632A1
(en)
|
2017-02-27 |
2018-08-30 |
Sandoz Ag |
Crystalline forms of valbenazine salts
|
|
WO2018164996A1
(en)
|
2017-03-06 |
2018-09-13 |
Neurocrine Biosciences, Inc. |
Dosing regimen for valbenazine
|
|
US11813232B2
(en)
|
2017-03-15 |
2023-11-14 |
Auspex Pharmaceuticals, Inc. |
Analogs of deutetrabenazine, their preparation and use
|
|
GB201705306D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
CA3057548A1
(en)
*
|
2017-04-01 |
2018-10-04 |
Adeptio Pharmaceuticals Limited |
Pharmaceutical compositions
|
|
GB201705304D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705305D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705303D0
(en)
*
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
GB201705302D0
(en)
|
2017-04-01 |
2017-05-17 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compositions
|
|
JOP20190239A1
(ar)
*
|
2017-04-19 |
2019-10-09 |
Neurocrine Biosciences Inc |
مركبات مثبطة لـ vmat2 وتركيبات منها
|
|
WO2018200605A1
(en)
|
2017-04-26 |
2018-11-01 |
Neurocrine Biosciences, Inc. |
Use of valbenazine for treating levodopa-induced dyskinesia
|
|
IL301770B2
(en)
|
2017-09-21 |
2024-06-01 |
Neurocrine Biosciences Inc |
High dose valbenazine formulation and related preparations, methods and kits
|
|
MY198713A
(en)
*
|
2017-10-10 |
2023-09-19 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
KR20250070134A
(ko)
|
2017-10-10 |
2025-05-20 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
특정 vmat2 억제제의 투여 방법
|
|
KR20210004939A
(ko)
*
|
2017-11-08 |
2021-01-13 |
포시 파마슈티컬스 컴퍼니 리미티드 |
다이하이드로테트라베나진의 에스터
|
|
EP3713938A1
(en)
|
2017-11-22 |
2020-09-30 |
Assia Chemical Industries Ltd |
Solid state form of valbenazine
|
|
EP3733666B1
(en)
|
2017-12-26 |
2022-09-21 |
Crystal Pharmaceutical (Suzhou) Co., Ltd. |
Crystal form of valbenazine di-p-toluenesulfonate, preparation method thereof and use thereof
|
|
CN110092785A
(zh)
*
|
2018-01-31 |
2019-08-06 |
广东东阳光药业有限公司 |
一种丁苯那嗪的动态拆分方法
|
|
GB201808464D0
(en)
|
2018-05-23 |
2018-07-11 |
Adeptio Pharmaceuticals Ltd |
Pharmaceutical compounds for use in treating huntington's disease
|
|
WO2019241555A1
(en)
|
2018-06-14 |
2019-12-19 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitor compounds, compositions, and methods relating thereto
|
|
SG11202100303QA
(en)
|
2018-08-15 |
2021-02-25 |
Neurocrine Biosciences Inc |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2020047198A1
(en)
|
2018-08-31 |
2020-03-05 |
Incyte Corporation |
Salts of an lsd1 inhibitor and processes for preparing the same
|
|
EP3860599B1
(en)
|
2018-10-04 |
2024-05-15 |
Adeptio Pharmaceuticals Limited |
(+)-alpha-dihydrotetrabenazine dosage regimen for treating movement disorders
|
|
CA3065236A1
(en)
|
2018-12-27 |
2020-06-27 |
Apotex Inc. |
Novel crystalline form of valbenazine dibesylate
|
|
WO2020213014A1
(en)
|
2019-04-19 |
2020-10-22 |
Mylan Laboratories Limited |
An improved process for the preparation of valbenazine and its salts
|
|
US10689380B1
(en)
|
2019-07-30 |
2020-06-23 |
Farmhispania S.A. |
Crystalline forms of valbenazine ditosylate
|
|
WO2021027792A1
(zh)
*
|
2019-08-12 |
2021-02-18 |
山东绿叶制药有限公司 |
Vmat2抑制剂及其制备方法和应用
|
|
US10940141B1
(en)
|
2019-08-23 |
2021-03-09 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain VMAT2 inhibitors
|
|
CN117736203A
(zh)
|
2019-09-13 |
2024-03-22 |
纽罗克里生物科学有限公司 |
用于合成缬苯那嗪的方法
|
|
CN110698397A
(zh)
*
|
2019-10-28 |
2020-01-17 |
南京红杉生物科技有限公司 |
丁苯那嗪中间体及其合成方法、应用和合成用中间产物
|
|
IL305054A
(en)
|
2021-03-22 |
2023-10-01 |
Neurocrine Biosciences Inc |
VMAT2 inhibitors and methods of use
|
|
WO2022232060A1
(en)
|
2021-04-26 |
2022-11-03 |
Neurocrine Biosciences, Inc. |
Processes for the synthesis of valbenazine
|
|
KR20240027780A
(ko)
|
2021-06-30 |
2024-03-04 |
뉴로크린 바이오사이언시즈 인코퍼레이티드 |
조현병의 부가적 치료에 사용하기 위한 발베나진
|
|
AU2022302155A1
(en)
|
2021-06-30 |
2024-02-08 |
Neurocrine Biosciences, Inc. |
Valbenazine for use in the treatment of dyskinesia due to cerebral palsy
|
|
WO2023172849A1
(en)
|
2022-03-07 |
2023-09-14 |
Neurocrine Biosciences, Inc. |
Valbenazine, a vmat2 inhibitor, as a free base a tosylate or ditosylate salt, for use in the treatment of chorea associated with huntington's disease
|
|
CN119907800A
(zh)
|
2022-09-21 |
2025-04-29 |
纽罗克里生物科学有限公司 |
六氢-2H-吡啶并[2,1-a]异喹啉VMAT2抑制剂及其使用方法
|
|
TW202521119A
(zh)
|
2023-08-17 |
2025-06-01 |
美商紐羅克里生物科學有限公司 |
用於投與特定vmat2抑制劑之方法
|
|
WO2025038959A1
(en)
|
2023-08-17 |
2025-02-20 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025096823A1
(en)
|
2023-11-01 |
2025-05-08 |
Neurocrine Biosciences, Inc. |
Improvement, maintenance or reduction of decline of motor function associated with huntington disease using valbenazine
|
|
WO2025188830A1
(en)
|
2024-03-06 |
2025-09-12 |
Neurocrine Biosciences, Inc. |
Methods for the administration of certain vmat2 inhibitors
|
|
WO2025199234A1
(en)
|
2024-03-20 |
2025-09-25 |
Neurocrine Biosciences, Inc. |
Vmat2 inhibitors and methods of use
|